Expression of the highly conserved RNA binding protein koc in embryogenesis

Müeller-Pillasch, Friederike; Pohl, Barbara; Wilda, Monika; Lacher, Ulrike; Beil, Michael; Wallrapp, Christine; Hameister, Horst; Knoechel, Walter; Adler, Guido; Gress, Thomas M.

doi:10.1016/s0016-5085(00)83257-6

Cited by 17 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that IMP family members play an important role in RNA trafficking and stabilization, cell growth, and cell migration during the early stages of embryogenesis. 16 IMP3 is normally expressed in developing epithelium, muscle and placenta during the early stages of human and mouse embryogenesis, but is expressed at low or undetectable levels in adult tissues. 29 Overex-pression of IMP3 is found in many malignant tumours, including pancreas, lung, stomach and colon cancers, endocervical adenocarcinoma, endometrial serous carcinoma, and soft tissue sarcomas, but not in adjacent benign tissues.…”

Section: Discussionmentioning

confidence: 99%

“…14 These IMP proteins all contain two RNA recognition motifs and four K-homology domains that allow them to bind RNAs strongly and specifically; however, only a few specific RNA targets, such as insulin-like growth factor II (IGF-II), have thus far been identified. 15,16 IMP3 has also been called KOC (K-homology domain protein overexpressed in cancer) and L523S. 15,17 IMP3 is an oncofetal protein involved in embryogenesis, and its expression is associated with a number of malignant neoplasms.…”

Section: Introductionmentioning

confidence: 99%

“…15,17 IMP3 is an oncofetal protein involved in embryogenesis, and its expression is associated with a number of malignant neoplasms. 15,16,[18][19][20][21][22][23][24][25][26] Our previous studies have shown that IMP3 is an important cancer-specific gene that is associated with aggressive and advanced cancers, and is specifically expressed in malignant tumours but is not found in adjacent benign tissues. [18][19][20][21][22]26 Moreover, in vitro studies have shown that IMP3 promotes tumour cell proliferation, adhesion, and invasion.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Differential expression of IMP3 between male and female mature teratomas—immunohistochemical evidence of malignant nature

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential expression of IMP3 between male and female mature teratomas—immunohistochemical evidence of malignant nature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…CRD-BP (also termed IGF-II mRNA BP) is closely related to the human KOC protein, which is overexpressed in pancreatic cancer (KH-domain containing protein Overexpressed in Cancer), and p62, a human hepatocellular carcinoma autoantigen (Lu et al, 2001). KOC is 84% identical to Vg1-RBP a Xenopus RNA binding protein involved in the localization of mRNA during development (Mueller-Pillasch et al, 1999). A recent review (Yaniv andYisraeli, 2002) describes this family of proteins in detail.…”

Section: C-mycmentioning

confidence: 99%

Post‐transcriptional regulation in cancer

Audic

Hartley

2004

Biology of the Cell

208

204

View full text Add to dashboard Cite

Deregulation of gene expression is a hallmark of the cancer cell. Acquiring a new profile of expressed proteins may enable the cell to re-enter the cell cycle, or give them a growth or motility advantage over "normal cells". An efficient and rapid way to alter gene expression is via regulation of mRNAs already transcribed. Modifications of mRNA stability and/or translational efficiency are increasingly reported in cancer. mRNA stability and translation are controlled through a complex network of RNA/protein interactions involving recognition of specific target mRNAs by RNA-BPs. We review how alterations in regulatory sequences, RNA-BPs, or in upstream signalling pathways affect the stability and/or translational efficiency of mRNAs encoding proto-oncogenes, cytokines, cell cycle regulators and other regulatory proteins to promote tumorigenesis and cancer progression.A more thorough understanding of post-transcriptional mechanisms such as these will enable the design and development of specific therapies based on modulating the translation or stability of specific mRNAs.

show abstract

“…This would be helpful in selecting patients who are best suited for adjuvant therapy and to spare Insulin-like growth factor II mRNA binding protein 3 (IMP3; also known as L523S) is a member of the insulin-like growth factor (IGF-II) mRNA binding protein (IMP) family that consists of IMP1, IMP2 and IMP3 [ 5 ] . During the early stages of embryogenesis, IMP family members are important in RNA traffi cking and stabilization, cell growth and cell migration [ 6 ] . IMP3 is expressed in developing muscle, epithelium and placenta during the early stages of human and mouse embryogenesis, but is expressed at low or undetectable concentrations in normal adult tissues [ 7 ] .…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of insulin‐like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy

Chromecki

Eugene²,

Pummer

et al. 2011

BJU International

View full text Add to dashboard Cite

Study Type – Prognosis (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Insulin‐like growth factor II mRNA binding protein 3 (IMP3) is associated with poor outcomes in a variety of malignancies. The role of IMP3 in protate cancer remains poorly understood. IMP3 expression was associated with features of aggressive biology and aggressive prostate cancer recurrence after surgery. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have independent prognostic value in patients treated with RP. OBJECTIVE To evaluate the association of insulin‐like growth factor II mRNA binding protein 3 (IMP3) with pathological features and outcomes in patients treated with radical prostatectomy (RP). PATIENTS AND METHODS Immunohistochemical staining for IMP3 was performed on archival tissue microarray specimens from 232 consecutive patients treated with RP for clinically localized disease. None of the patients received neoadjuvant or adjuvant radiation or hormone therapy. IMP3 expression was histologically categorized as normal or abnormal. Disease recurrence was classified as aggressive if metastases were present, post‐recurrence prostate‐specific antigen (PSA) doubling time was less than 10 months, or if the patients failed to respond to salvage local radiation therapy. RESULTS The median follow‐up was 69.8 months (interquartile range [IQR]: 40.1–99.5). IMP3 expression was abnormal in 42 (18.1%) of 232 patients. IMP3 expression was associated with extracapsular extension (P= 0.020), seminal vesicle invasion (P= 0.024), lymphovascular invasion (P= 0.036) and a high pathological Gleason score (P= 0.009). The 5‐year PSA recurrence‐free survival for IMP3‐negative patients was 83% (standard error [SE]= 3) vs 67% (SE = 8) in IMP3‐positive patients (log‐rank test, P= 0.015). In a multivariable analysis that adjusted for the effects of surgical margins, extracapsular extension and seminal vesicle invasion, PSA (hazard ratio [HR]: 1.04, P= 0.013), lymph node metastasis (HR: 16.7, P < 0.001) and a high pathological Gleason score (HR 4.3, P= 0.008) were significantly associated with PSA recurrence‐free survival, whereas IMP3 expression was not (P= 0.11). Similarly, IMP3 expression was only associated with aggressive recurrence (HR 3.2, P= 0.006). CONCLUSION IMP3 expression is abnormal in approximately one‐fifth of prostate cancers. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have an independent prognostic value in patients treated with RP.

show abstract

Expression of the highly conserved RNA binding protein koc in embryogenesis

Cited by 17 publications

References 0 publications

Differential expression of IMP3 between male and female mature teratomas—immunohistochemical evidence of malignant nature

Differential expression of IMP3 between male and female mature teratomas—immunohistochemical evidence of malignant nature

Post‐transcriptional regulation in cancer

Prognostic value of insulin‐like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy

Contact Info

Product

Resources

About